SIGLEC10 and central nervous system cancer: Figure 2B displays the clinical forest of siglec10 expression in glioma patients. The hsiglec10 expression had shorter survival prognosis than the low siglec10 expression in patients with grade 4 (p = 0.003), GBM (p = 0.003), ATRX loss (p < 0.001), no radiotherapy (p = 0.022), or no chemotherapy (p = 0.016).